Inhibrx Biosciences, Inc.
No enriched coverage for $INBX in the last 7 days.
Lappe Mark (Chief Executive Officer) purchased 10,040 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $84.56 ($84.07–$85.76, $0.85M total) across 6 trades on 2026-10-14.
Inhibrx Biosciences (INBX) will present updated data on INBRX-106 and INBRX-109 at global oncology conferences. The presentations aim to validate mid-stage data and influence investor sentiment. The company faces risks including heavy losses and reliance on external financing, with shares potentially trading at a premium according to a valuation report.
Lappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.
Recent INBX coverage spans insider activity, financial news and technology.
In the last 30 days, INBX insiders filed 11 SEC Form 4 transactions — 11 purchases ($2.3M) and no sales. The most active reporter was Lappe Mark, Chief Executive Officer, with 10 filings.
Insider buying suggests confidence and may support the stock price.
The stock may experience short‑term volatility as investors price in the upcoming data.
The insider purchase suggests confidence from management and may create modest buying pressure.
Positive trial data de‑risk the program but the unexpected price decline suggests short‑term sell pressure.
Small insider buy, limited market impact.
AlphAI scores every news story that mentions INBX with an AI model for sentiment and relevance, and aggregates insider trades from Inhibrx Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lappe Mark (Chief Executive Officer) purchased 10,040 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $84.56 ($84.07–$85.76, $0.85M total) across 6 trades on 2026-10-14.
1 min readInhibrx Biosciences (INBX) will present updated data on INBRX-106 and INBRX-109 at global oncology conferences. The presentations aim to validate mid-stage data and influence investor sentiment. The company faces risks including heavy losses and reliance on external financing, with shares potentially trading at a premium according to a valuation report.
2 min readLappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.
1 min readInhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.
3 min readCapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.
2 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-23.
1 min readOn September 15-16, 2026, insiders made notable transactions: Avenue RP Opportunities Fund and director Par Chadha bought XBP Global Holdings (XBP) shares at $2.83 each, totaling $1.5M and $580K respectively. Directors at Agree Realty (ADC) bought shares near its 52-week low. A director at Inhibrx (INBX) bought 5K shares at $100 each. A director at CrowdStrike (CRWD) sold 119K shares for $28.6M. Silver Lake Partners sold Dell (DELL) shares for $28M. A 10% owner of Talos Energy (TALO) sold 1.38M
2 min readKayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-16.
1 min readMANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.
1 min readMANHARD KIMBERLY sold 1,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $115.47 ($115.14–$115.80, $0.12M total) across 2 trades over 2026-09-08 to 2026-09-09.
1 min read
